VERA News

The IPO market had a tumultuous week with five IPOs and three postponements: Brazilian customer service platform Zenvia (ZENV), mortgage insurance spinoff Enact Holdings (ACT), and hearing care services provider hear.com (HCG). SPAC activity remained steady, with two blank check IPOs raising $430 million. New filers continued...read more

Vera Therapeutics, a Phase 2b biotech developing fusion proteins for immunological diseases, raised $48 million by offering 4.4 million shares at $11, below the range of $14 to $16. At pricing, the company commands a fully diluted market value of $244 million. Vera's lead candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that...read more

Vera Therapeutics, a Phase 2b biotech developing fusion proteins for immunological diseases, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $65 million by offering 4.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Vera Therapeutics would command a fully diluted market value of $335...read more

Updated Monday, 5/10. Eight IPOs are slated to raise $1.6 billion in the week ahead, led by private mortgage insurance company Enact Holdings (ACT). The largest deal of the week, Enact Holdings (ACT) plans to raise $497 million at a $3.6 billion market cap. Being spun out of Genworth Financial, Enact is a leading private...read more